Vericel stock hits 52-week low at 34.49 USD

Published 01/08/2025, 14:34
Vericel stock hits 52-week low at 34.49 USD

Vericel (NASDAQ:VCEL) Corp’s stock reached a 52-week low, trading at 34.49 USD, marking a significant drop from its 52-week high of 63 USD. According to InvestingPro data, the company maintains strong financial health with a current ratio of 4.97x, indicating robust liquidity. This milestone reflects a challenging year for the company, as the stock has experienced a significant decline, with a 1-year change of -26.63%. Despite the recent pressure, analysts remain optimistic, with targets ranging from 49 USD to 67 USD. The drop to this 52-week low highlights the volatility and pressures faced by Vericel in the market over the past year, as investors continue to assess the company’s performance and future prospects. For deeper insights and 13 additional ProTips on Vericel, including detailed valuation metrics and growth indicators, check out the comprehensive Pro Research Report available on InvestingPro.

In other recent news, Vericel Corporation reported its second-quarter earnings for 2025, showing a narrowed net loss and an increase in revenue. The earnings per share (EPS) was a loss of $0.01, which surpassed analyst projections of a $0.03 loss. However, the revenue came in slightly below expectations at $63.24 million, compared to the anticipated $64.61 million. Despite these financial results, Canaccord Genuity adjusted its price target for Vericel’s stock from $61.00 to $58.00, maintaining a Buy rating. The adjustment was influenced by mixed performance across Vericel’s product lines. While the company exceeded bottom-line expectations, its MACI product fell short of revenue targets. Additionally, Epicel’s revenue was lower than expected, despite achieving the highest number of biopsies in any quarter since 2023. These developments reflect Vericel’s ongoing challenges and achievements within its market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.